- Main
Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial
- Statland, Jeffrey M;
- Moore, Dan;
- Wang, Yunxia;
- Walsh, Maureen;
- Mozaffar, Tahseen;
- Elman, Lauren;
- Nations, Sharon P;
- Mitsumoto, Hiroshi;
- Fernandes, J Americo;
- Saperstein, David;
- Hayat, Ghazala;
- Herbelin, Laura;
- Karam, Chafic;
- Katz, Jonathan;
- Wilkins, Heather M;
- Agbas, Abdulbaki;
- Swerdlow, Russell H;
- Santella, Regina M;
- Dimachkie, Mazen M;
- Barohn, Richard J;
- Consortium, The Rasagiline Investigators of the Muscle Study Group and Western ALS
Published Web Location
https://doi.org/10.1002/mus.26335Abstract
INTRODUCTION: Rasagiline is a monoamine oxidase B (MAO-B) inhibitor with possible neuroprotective effects in patients with amyotrophic lateral sclerosis (ALS). METHODS: We performed a randomized, double-blind, placebo-controlled trial of 80 ALS participants with enrichment of the placebo group with historical controls (n = 177) at 10 centers in the United States. Participants were randomized in a 3:1 ratio to 2 mg/day rasagiline or placebo. The primary outcome was average slope of decline on the ALS Functional Rating Scale-Revised (ALSFRS-R). Secondary measures included slow vital capacity, survival, mitochondrial and molecular biomarkers, and adverse-event reporting. RESULTS: There was no difference in the average 12-month ALSFRS-R slope between rasagiline and the mixed placebo and historical control cohorts. Rasagiline did not show signs of drug-target engagement in urine and blood biomarkers. Rasagiline was well tolerated with no serious adverse events. DISCUSSION: Rasagiline did not alter disease progression compared with controls over 12 months of treatment. Muscle Nerve 59:201-207, 2019.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.